Company Overview
Company Name
atDose Co., Ltd.
CEO
Hidenori Nakamura
Business Activities
Manufacturing of medical devices
License for Manufacturing and Sales of Class I Medical Devices: 14B1X10026
Established
2017.9.1
Capital
JPY 8.6 million
Location
Head Office
Asahi-ku, Yokohama, Kanagawa Prefecture
Research Institute
KBIC (Kawasaki Business Incubation Center) #225, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki, Kanagawa Prefecture
Business Development Base
231 Rokugo BASE, 3-10-16 Minami Rokugo, Ota-ku, Tokyo
Mission Statement
At atDose, we envision a future where we can thrive alongside our chronic conditions. A future where treating cancer, retinal detachment, and any other diseases, does not limit the quality of time with our loved ones.
We believe that, by providing patient-centric treatment, we can create such a world where patients do not have to give up on their dreams and happiness.
What We
Will Realize
Our core technology, the Electro-Osmotic pump, allows the precise administration of ultra-small doses of medication to specific areas with a strong steady force. It enables the manipulation of high-viscosity medicinal fluids using thin needles, such as 27G. As a result, we anticipate effects such as reducing the side effects of chemotherapy. We aim to realize minimally invasive, patient-centric, and compassionate healthcare.
Team
Hidenori Nakamura
Founder&CEO
Mamoru Hirafuji
Founder&CTO
Abhijit Deshpande
COO
Kazuhiro Dannoue
CMO
Satoshi Nakamichi
R&D Manager
Yoshimasa Hamano
Manager, Medical Device
Sumito Yamada
Executive Director
Rokuro Manabe
Chief of QMS
Yoshiyuki Katsuragi
Non-executive Director
Taizo Fukushima
Audit & Supervisory Board Member
Yoshihiko Kurokawa
Legal Counsel
Shigeyuki Yamashita
Intellectual Property
Takeshi Murotani
Financial Manager
Dr. T. Jeevanandam
Senior Advisor
History
2022.8.4
Established the Indian subsidiary.
2022.1.25
Received the Kanagawa Prefecture Governor’s Award at the “Kanagawa Business Audition 2022.”
2021.11.04
Selected for the JETRO “Concentrated Support Program for Overseas Expansion.”
2021.8.31
Conducted an additional fundraising of JPY 140 million.
2020.10.28
Renewed the logo and website.
2020.8.31
Conducted fundraising of JPY 55.5 million.
2020.8.6
Launched three products: atDose Core, Mobile, and Multi.
2020.7.22
Obtained a license for the manufacture and sale of medical devices.
2020.3.29
Featured in the program “Change the World – Building the Future.”
2020.2.22
Received the Audience Award at the Yokohama Business Grand Prix.
2019.12.26
Selected for the YOXO Accelerator Program.
2019.10.10
Commenced collaborative development of equipment for animal experiments with three companies.
2019.9.21
Company Award in TECH PLANTER
2019.7.25
Selected for the Yokohama Acceleration Program.
2019.7.4
Selected for “The Springboard™ Program in Yokohama.”
2019.6.12
Selected for KISTEC research projects.
2019.1.18
Selected for NEDO NEP.
2018.9.1
Established a research institute at KBIC.
2018.1.22
Launched atDose in 2017 with a Silicon Valley dispatch.
2017.9.1
Launched atDose.
